Dova Pharmaceuticals, which is commercializing an acquired drug candidate for low blood platelets, announced terms for its IPO on Monday.
The Durham, NC-based company plans to raise $65 million by offering 4.1 million shares at a price range of $15 to $17. Insiders intend to purchase $25 million worth of shares in the offering. At the midpoint of the proposed range, Dova Pharmaceuticals would command a fully diluted market value of $415 million.
Dova Pharmaceuticals was founded in 2016 and plans to list on the Nasdaq under the symbol DOVA. J.P. Morgan, Jefferies and Leerink Partners are the joint bookrunners on the deal. It is expected to price during the week of June 26, 2017.
